Navigation Links
Arno Therapeutics Reports 2008 Year-End Financial Results
Date:3/31/2009

PARSIPPANY, N.J., March 31 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced its financial results for the year ended December 31, 2008.

For the year ended December 31, 2008, Arno reported a net loss of $12.9 million, or $0.81 per share, compared to a net loss of $3.4 million, or $0.34 per share, for the year ended 2007. Total operating expenses for the year ended December 31, 2008 were $12.1 million, an increase of $8.8 million compared to the year ended 2007. Included in operating expenses for the years ended December 31, 2008 and 2007 were non-cash stock-based compensation expenses of $1.1 million and $0.1 million, respectively. The increase in operating expenses in 2008 was primarily attributed to clinical and pre-clinical development expenses of our three drug candidates, merger related fees and increased headcount.

Total research and development expenses for the year ended December 31, 2008 were $9.8 million, compared to $2.9 million in 2007. Research and development expenses for the years ended 2008 and 2007 included non-cash stock-based compensation expenses of $0.5 million and $0.1 million, respectively. The increase in research and development expenses of $6.9 million for the year ended 2008 compared to 2007 was primarily attributed to clinical development costs associated with AR-67, our lead clinical development compound which has completed Phase I enrollment, in addition to the in-licensing and pre-clinical development costs associated with our other two drug candidates AR-12 and AR-42, which we in-licensed in 2008.

General and administrative expenses for the year ended 2008 were $2.3 million compared to $0.4 million for the year ended 2007. General and administrative expenses for the years ended 2008 and 2007 included non-cash stock-based compensation expenses of $0.7
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
2. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
3. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
4. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
5. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
6. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
7. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
8. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
9. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
10. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
(Date:9/17/2014)... PA & Rockville, MD (PRWEB) September 17, 2014 ... won a Small Business Innovation Research (SBIR) grant to ... immunotherapy. The award will provide ITI with approximately $255,000 ... Tree nuts, a leading cause of food allergy, affect ... cause of anaphylaxis behind peanut allergy. Tree nut exposure ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Escape Alert, LLC . filed international patents ... alert owners if their pet has escaped and enable them to ... in the pet’s body. This is the first implantable microchip ... been around for many years, they are passive until read by ... a pet’s location or alert the owner that the pet has ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... train workforce, stimulate economy ALEXANDRIA, Va., May 7 ... budget request, proposing level funding for the Carl D. ... $1.3 billion. The Perkins Act is the primary source ... connect education and real-world careers. The Association for Career ...
... May 7 Elsevier,one of the world,s leading ... and services, announced today that Michael Hansen,CEO of ... in,light of recent allegations of improper Australia based ... "Elsevier prides itself on ...
... 7 The Sixth Annual Healthcare Unbound Conference & ... will feature the coming together of consumer and healthcare ... The Conference will take place at the Seattle ... Attendees will include a diverse representation of the ...
Cached Biology Technology:Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 3
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
(Date:9/16/2014)... of severe maternal morbidity amongst women in Australia ... new study published today (17 September) in ... . , Australians generally enjoy high standards of ... disparities exist, in particular between indigenous and non ... explore the independent impact of socioeconomic position on ...
(Date:9/16/2014)... The 36 Pit Fire began on September 13, 2014. ... It is currently over 2,300 acres in size and ... The 36 Pit Fire was calm Monday night due to ... establishing an anchor point and beginning to construct a fireline ... The following resources are working on the fire: , 7 ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... at levels consumed by breast cancer patients and survivors in ... rats, new research found., The role of folate, a ... development and progression of breast cancer is highly controversial. ... breast cancer, recent studies have suggested that taking high amounts ...
... When the temperature rises on Baffin Island, in the ... ice for thousands of years, are exposed. Using radiocarbon ... has calculated the age of relic moss samples that ... moss samples would have been destroyed by erosion had ...
... the Montreal Neurological Institute and Hospital in Canada ... Parkinson,s disease are involved in the early-stage quality ... reported in T he EMBO Journal , removes ... mitochondria., "PINK1 and parkin, are implicated in selectively ...
Cached Biology News:Large amounts of folic acid shown to promote growth of breast cancer in rats 2Quality control of mitochondria as a defense against disease 2
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
... 2 products into 1:, , A multi-tube ... kit , ,The FastPrep System consists ... System Matrix and Isolation Kits. Samples are ... eliminating the use of metal probes and ...
... Blood bank refrigerators: ,Each upright ... and superior 4C temperature uniformity for refrigerated ... HemaPro 2000 Surveillance Module for complete blood ... BBR37 are equipped with the HemaPro 101 ...
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
Biology Products: